Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 12/20 | 0.59 |
| ▸ | GSK3B | P49841 | 4/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 8/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7569131 | 0.86 | PTGS2 (0.43) | PTGS2GSK3BPTGS1ALDH1A1 | |
| SCHEMBL7573858 | 0.83 | PTGS2 (0.61) | PTGS2GSK3BPTGS1KDM4EALDH1A1 | |
| SCHEMBL7568009 | 0.83 | PTGS2 (0.61) | PTGS2GSK3BPTGS1KDM4EALDH1A1 | |
| SCHEMBL7565527 | 0.81 | PTGS2 (0.51) | PTGS2GSK3BPTGS1ALDH1A1GAA | |
| SCHEMBL7565471 | 0.79 | PTGS2 (0.56) | PTGS2GSK3BPTGS1ALDH1A1MAPT | |
| SCHEMBL6274595 | 0.77 | PTGS2 (0.71) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL6473400 | 0.77 | PTGS2 (0.71) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL7573008 | 0.77 | PTGS2 (0.57) | PTGS2GSK3BPTGS1KDM4EALDH1A1 | |
| SCHEMBL7566102 | 0.77 | PTGS2 (0.57) | PTGS2GSK3BPTGS1KDM4EALDH1A1 | |
| SCHEMBL7575463 | 0.75 | PTGS2 (0.51) | PTGS2GSK3BPTGS1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9421266-B2 | Safety of pseudoephedrine drug products | PISGAH LABORATORIES, INC. (US) | 2016-08-23 | — | — | US | claimed |
| US-20140178480-A1 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS | PISGAH LABORATORIES, INC. | 2014-06-26 | — | — | US | claimed |
| US-6521685-B1 | Clarifying agent formulations for thermoplastics exhibiting very high nucleation efficacy | MILLIKEN & COMPANY | 2003-02-18 | — | — | US | claimed |
| EP-0889878-B1 | BISARYLCYCLOBUTENE DERIVATES AS CYCLOOXYGENASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2002-09-04 | — | — | EP | claimed |
| WO-2000029022-A1 | COX-2 INHIBITORS IN COMBINATION WITH CENTRALLY ACTING ANALGESICS | ALGOS PHARMACEUTICAL CORPORATION (US) | 2000-05-25 | — | — | WO | claimed |
| US-5817700-A | ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1998-10-06 | — | — | US | claimed |
| US-9421266-B2 | Safety of pseudoephedrine drug products | PISGAH LABORATORIES, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20140178480-A1 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS | PISGAH LABORATORIES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-6972306-B2 | Compositions and articles comprising asymmetric dipolar multi-substituted alditol derivatives | MILLIKEN & COMPANY (US) | 2005-12-06 | — | — | US | disclosed |
| US-20050100594-A1 | Pharmaceutical formulation containing muscle relaxant and COX-II inhibitor | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-05-12 | — | — | US | disclosed |
| US-20050096371-A1 | Topical pharmaceutical compositions | GLENMARK PHARMACEUTICALS LIMITED (IN) | 2005-05-05 | — | — | US | disclosed |
| US-20030114558-A1 | Compositions and articles comprising asymmetric dipolar multi-substituted alditol derivatives | DOTSON DARIN L (US) | 2003-06-19 | — | — | US | disclosed |
| US-6521685-B1 | Clarifying agent formulations for thermoplastics exhibiting very high nucleation efficacy | MILLIKEN & COMPANY | 2003-02-18 | — | — | US | disclosed |
| US-6500964-B2 | BY REACTING SUBSTITUTED BENZALDEHYDE(S) WITH ALDITOL(S) SUCH AS SORBITOL | MILLIKEN & COMPANY | 2002-12-31 | — | — | US | disclosed |
| EP-0889878-B1 | BISARYLCYCLOBUTENE DERIVATES AS CYCLOOXYGENASE INHIBITORS | MERCK FROSST CANADA INC (CA) | 2002-09-04 | — | — | EP | disclosed |
| US-5817700-A | ANTIINFLAMMATORY AGENTS | MERCK FROSST CANADA, INC. (CA) | 1998-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140178480-A1 | SAFETY OF PSUEDOEPHEDRINE DRUG PRODUCTS | SORD, ABCB11, ABCB1 | PTGS2 2503/4885GSK3B 3731/4885PTGS1 1385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.